BiotechTube
Home/Kinnov Therapeutics/Prof. Wim van den Brink
PW

Prof. Wim van den Brink

Key Opinion Leader; Professor Emeritus of Psychiatry and Addiction at Academic Medical Center, University of Amsterdam

Kinnov Therapeutics

Therapeutic Areas

AddictionPsychiatryCentral Nervous System

Kinnov Therapeutics Pipeline

DrugIndicationPhase
KT-110Alcohol Use Disorder (AUD) - SeverePhase 3
KT-110 (New Galenic Form)Alcohol Use Disorder (AUD)Formulation Testing

Leadership Team at Kinnov Therapeutics

ED
Emmanuel de Rivoire
Managing Director
AP
Alain Puech
Medical Director
PH
Prof. Henri-Jean Aubin
Principal Investigator for Phase 2 trial; Professor of Psychiatry and Addictology at Hôpital Pitié-Salpêtrière
JG
Julien Guiraud
Co-author of Phase 2 publication; Vergio Consulting
PK
Prof. Karl Mann
Key Opinion Leader; Professor Emeritus at Central Institute of Mental Health, University of Heidelberg
PA
Prof. Antoni Gual
Key Opinion Leader; Head of the Addictions Unit Neurosciences Institute at University of Barcelona
PR
Prof. Raymond Anton
Key Opinion Leader; Professor Emeritus of Psychiatry and Addictions at Medical University of South Carolina
View full Kinnov Therapeutics profile